HC Wainwright & Co. downgraded Celcuity Inc (CELC) to Neutral from Buy on November 16, 2025. The stock is currently priced at $92.68.
This downgrade underscores increased caution regarding Celcuity's outlook, potentially reflecting concerns about competitive pressures and execution risks that may impact performance.
Celcuity operates as a cellular analysis company based in Minneapolis, focusing on innovative treatments for advanced breast cancer and prostate cancer. Its lead candidate, gedatolisib, targets specific cancer pathways and is currently in a Phase III clinical trial, VIKTORIA-1, evaluating its effectiveness in combination with other therapies.
The company's market capitalization stands at $3.1 billion, with a trailing twelve-month EPS of -3.45. Upcoming earnings are scheduled for August 11, 2026, with an EPS estimate of -1.15 and revenue forecast of $765,000.
Analyst consensus remains at Buy, with 6 Strong Buy, 8 Buy, and 1 Hold ratings. This update provides insight into the evolving sentiment surrounding Celcuity as it navigates a competitive biotech landscape.